AURORA, ON--(Marketwired - Sep 25, 2014) - Helix BioPharma Corp. (
Robert Verhagen, President and CEO, will give a corporate presentation of the Company's capabilities in the development of novel cancer therapeutics. A copy of the presentation will be made available on the Company's website at www.helixbiopharma.com following completion of Mr. Verhagen's presentation.
About Helix BioPharma Corp.
Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha-2b. Helix is currently listed on the TSX and FSE under the symbol "HBP".
Contact Information:
Investor Relations:
Helix BioPharma Corp.
Tel: 905 841-2300
Email: ir@helixbiopharma.com